Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma | Zendy

Atsushi Hiraoka | Zendy; Takashi Kumada | Zendy; Toshifumi Tada | Zendy; Chikara Ogawa | Zendy; Joji Tani | Zendy; Shinya Fukunishi | Zendy; Masanori Atsukawa | Zendy; Masashi Hirooka | Zendy; Kunihiko Tsuji | Zendy; Toru Ishikawa | Zendy; Koichi Takaguchi | Zendy; Kazuya Kariyama | Zendy; Ei Itobayashi | Zendy; Kazuto Tajiri | Zendy; Noritomo Shimada | Zendy; Hiroshi Shibata | Zendy; Hironori Ochi | Zendy; Kazuhito Kawata | Zendy; Hidenori Toyoda | Zendy; Hideko Ohama | Zendy; Kazuhiro Nouso | Zendy; Akemi Tsutsui | Zendy; Takuya Nagano | Zendy; Norio Itokawa | Zendy; Korenobu Hayama | Zendy; Taeang Arai | Zendy; Michitaka Imai | Zendy; Yohei Koizumi | Zendy; Shinichiro Nakamura | Zendy; Kojiro Michitaka | Zendy; Yoichi Hiasa | Zendy; Masatoshi Kudo | Zendy

Open Access

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma

Author(s) -

Atsushi Hiraoka,

Takashi Kumada,

Toshifumi Tada,

Chikara Ogawa,

Joji Tani,

Shinya Fukunishi,

Masanori Atsukawa,

Masashi Hirooka,

Kunihiko Tsuji,

Toru Ishikawa,

Koichi Takaguchi,

Kazuya Kariyama,

Ei Itobayashi,

Kazuto Tajiri,

Noritomo Shimada,

Hiroshi Shibata,

Hironori Ochi,

Kazuhito Kawata,

Hidenori Toyoda,

Hideko Ohama,

Kazuhiro Nouso,

Akemi Tsutsui,

Takuya Nagano,

Norio Itokawa,

Korenobu Hayama,

Taeang Arai,

Michitaka Imai,

Yohei Koizumi,

Shinichiro Nakamura,

Kojiro Michitaka,

Yoichi Hiasa,

Masatoshi Kudo

Publication year - 2020

Publication title -

gastroenterology report

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.934

H-Index - 26

eISSN - 2052-0034

pISSN - 2304-1412

DOI - 10.1093/gastro/goaa042

Subject(s) - ramucirumab , lenvatinib , medicine , hepatocellular carcinoma , gastroenterology , oncology , discontinuation , sorafenib , cancer

Lenvatinib is used for unresectable hepatocellular carcinoma (u-HCC) as first-line, as well as second- and third-line therapy in Japan. We evaluated the therapeutic efficacy of newly developed ramucirumab when given after lenvatinib for post-progression treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research